Syndax Pharmaceuticals Inc
$ 20.81
-1.89%
24 Jul - close price
- Market Cap 1,843,975,000 USD
- Current Price $ 20.81
- High / Low $ 21.44 / 20.57
- Stock P/E N/A
- Book Value 0.47
- EPS -2.74
- Next Earning Report 2026-08-03
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.25 %
- ROE -1.90 %
- 52 Week High 25.59
- 52 Week Low 9.42
About
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. The company is headquartered in Waltham, Massachusetts.
Analyst Target Price
$39.45
Next Quarterly Earnings
| Jun 2026 | |
|---|---|
| Reported Date | 2026-08-03 |
| Fiscal Date Ending | 2026-06-30 |
| Estimated EPS | -0.45 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: SNDX
2026-07-26 07:09:43
Syndax Pharmaceuticals (NASDAQ:SNDX) has received an average rating of "Moderate Buy" from thirteen brokerages, with an average 1-year price target of $42.55. Despite recent analyst upgrades and reaffirmed ratings, the stock was down 1.9% at $20.81, and quarterly revenue missed expectations, although EPS beat estimates. Insider selling has also been noted in recent months.
2026-07-25 16:40:38
Syndax Pharmaceuticals Inc (SNDX) is trading at $20.81, down 1.89%, with a market capitalization of $1.82 billion. The company, focused on cancer therapies like Revuforj and Niktimvo, is rated as a "Buy" by analysts with a target price of $40.545, indicating a high upside potential. Despite an average stock market performance recently, its fundamentals are stable, and growth potential is considered high, though institutional selling has been noted alongside high institutional ownership.
2026-07-25 10:41:50
Granahan Investment Management LLC reduced its stake in Syndax Pharmaceuticals (NASDAQ:SNDX) by 16.5% during the first quarter, selling 60,472 shares and retaining 306,321 shares valued at $7.16 million. This reduction comes amid other institutional investors making varied changes to their positions and recent insider selling by the company's CMO and CEO. Syndax Pharmaceuticals recently reported a smaller-than-expected loss of ($0.48) per share and a significant 224.3% year-over-year revenue increase to $64.86 million.
2026-07-25 02:40:38
This article provides a revenue breakdown for Syndax Pharmaceuticals, Inc. (NASDAQ: SNDX). The company generated $172.35 million USD last year, primarily from its Pharmaceuticals segment and the United States market. This marks a significant increase from the previous year's revenue of $23.68 million USD.
2026-07-24 19:41:50
This article provides a brief financial update on Syndax Pharmaceuticals Inc (SWB:1T3) from the Stuttgart Stock Exchange, specifically focusing on its "Price to sales forward" metric. The content indicates that the market is closed, with no trades, and offers a link to view the financial data.
2026-07-22 06:40:17
Syndax Pharmaceuticals (SNDX) recently held an R&D event, unveiling two new drug candidates: SNDX-4321 for EGFR-mutant NSCLC and SNDX-62122 for myelofibrosis, alongside updates on its late-stage programs. These additions aim to diversify its pipeline beyond existing commercial assets, targeting difficult-to-treat cancers with high unmet needs. While the company's investment narrative remains centered on its current products, the new assets indicate a strategic push for deeper engagement in the menin franchise and expansion into new areas, potentially reshaping its long-term growth trajectory amidst ongoing net losses to fund R&D.
